Stockreport

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 [Yahoo! Finance]

Kyverna Therapeutics, Inc.  (KYTX) 
PDF Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate by year-end 2025 EMERYVILLE, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kyver [Read more]